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INTRODUCTION
Mucins, the major epithelial luminal surface glycoprotein
with a high molecular weight, are oligosaccharides attached
to serine or threonine residues of the apomucin protein back-
bone by O-glycosidic linkages (1, 2). During the past sever-
al years, a number of human mucins (MUC1-MUC9) have
been identified (3-7). MUC1 is a membrane-associated gly-
coprotein with an extracellular domain consisting of a vari-
able number of highly conserved tandem repeats of 20
amino acids (8, 9). MUC1 expression is up-regulated in a
variety of cancers including colorectal cancers and breast
cancers (10, 11). MUC2 glycoprotein is a secretory mucin,
containing two distinct regions with a high degree of inter-
nal homology. Region 1 consists mostly of 48-bp repeats
and region 2 is composed of 69-bp tandem repeats (12).
MUC2 apomucin  is expressed by adenomas and mucinous
carcinomas of the colorectum, but the expression of MUC2
may be associated with less aggressive biological properties in
non-mucinous adenocarcinoma of the colorectum (13, 14).
It is widely accepted that multiple genetic alterations under-
lie colorectal carcinogenesis. The p53 mutation is common
in human cancers and overexpression of its products is detect-
ed in many colorectal cancers. Thus, the immunohistochem-
ical detection of the overexpression of p53 is a useful marker
for the diagnosis of carcinoma (15, 16). However, the rela-
tionship between the p53 overexpression and metastasis in
colorectal cancers is still controversial (17, 18). There have
been few reports about the relation between the p53 overex-
pression and MUC1, MUC2 expression in colorectal cancers
(19).
In this study, we examined the relationship between the
expression of MUC1, MUC2, and p53 in colorectal carcino-
mas with special reference to regional lymph node metastasis.
MATERIALS AND METHODS
Representative samples of paraffin-embedded tissues were
obtained from the files of 97 colorectal cancer patients under-
going tumor resection at the Department of Surgery, Hal-
lym University, Sacred Heart Hospital and Hangang Sacred
Heart Hospital. Fifty-three were male and the remaining
44 were female. The mean age was 65 yr with a range of 33
to 89 yr. The tumor sites were the cecum in 12, ascending
colon in 14, descending colon in one, sigmoid colon in 28,
and rectum in 42 patients. The depth of tumor invasion
was submucosal (pT1) in 12, muscularis propria (pT2) in
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Coexpression of MUC1 with p53 or MUC2 correlates with Lymph
Node Metastasis in Colorectal Carcinomas 
The alteration of the mucin profile have been known to play a role in colorectal
carcinogenesis. MUC1 is up-regulated and MUC2 is down-regulated in colorec-
tal carcinomas. Overexpression of p53 is frequently noted in colorectal carcino-
mas with deep invasion or lymph node metastasis. However, there have been
few reports about the association between MUC1, MUC2, and p53 expression
with respect to the metastatic potential. This study was aimed to investigate the
relationship of MUC1, MUC2, and protein p53 expressions with clinicopathologi-
cal factors in colorectal carcinomas. Expressions of MUC1, MUC2, and p53 pro-
tein were examined immunohistochemically. Of total 97 cancers, 44 (45%) were
MUC1 positive, 39 (40%) were MUC2 positive and 58 (59%) showed a p53
overexpression. Coexpression of MUC1 with p53 and dual expression of MUC1
with MUC2 were associated with a higher frequency of lymph node metastasis
(p<0.05). The right colon showed a higher MUC1 positivity and frequent lymph
node metastasis than the left colon (p<0.05). These results suggest that the
coexpression of MUC 1 with p53 or MUC2 are involved in regional lymph node
metastasis in colorectal carcinomas. The high expression of MUC1 in the right
colon cancer was revealed to relate with lymph node metastasis.
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21, subserosa (pT3) in 61 and serosa exposed (pT4) in 3.
Forty-four cases had lymph node metastasis, and the remain-
ing 53 cases had no lymph node metastasis. For MUC1,
MUC2, and p53 immunostaining, paraffin-embedded sec-
tions were placed on poly-L-lysine-coated glass slides and
air-dried at room temperature. Deparaffinized and rehydrat-
ed sections were heated in a microwave oven for 5-min twice
in citrate buffer to retrieve antigenic activity and cooled for
60 min at room temperature. Endogenous peroxidase activ-
ity was inhibited by incubation with 1.5% hydrogen perox-
ide for 10 min at room temperature. After blocking non-
specific reactions with 10% normal rabbit serum for 20 min,
the sections were first incubated with MUC1 antibody (mouse
monoclonal antibody Ma552; Novocastra Laboratories, New
Castle, U.K.) at a dilution of 1:100, MUC2 antibody
(mouse monoclonal antibody Ccp58; Novocastra) at a dilu-
tion of 1:100, and p53 antibody (mouse monoclonal anti-
body BP53. 12; Zymed, San Francisco, U.S.A.) at a dilution
of 1:100. The sections were then incubated with biotinylat-
ed rabbit antimouse immunoglobulin for 30 min, followed
by streptavidin-peroxidase complex (DAKO, U.S.A.) for 30
min. The sections were carefully rinsed with several changes
of phosphate-buffered saline (PBS) between each step of the
procedure. The color was developed with diaminobenzidine.
The sections were lightly counterstained with hematoxylin
and mounted. The extent of MUC1 and MUC2 expression
was graded semiquantitatively as follows: 0, no positive
cells; 1, positive in less than 5% of cells; 2, positive in 5-
30% of cells; 3, positive in 30-60% of cells; 4, positive in
more than 60% of cells. For the purpose of relating MUC1
and MUC2 reactivity with pathological variables, cancers
were regarded as positive when the score was at least 3, accord-
ing to the previous reports (20). The p53 positivity was
defined as cells with brown staining on the nuclei, regard-
less of the staining intensity, but cells with very weak equiv-
ocal staining were considered negative. Staining pattern of a
diffuse type (cells with positive nuclear staining present dif-
fusely in most areas of the tumor) or nested type (>20 posi-
tive cells aggregated in a part of the tumor) was regarded as
having p53 protein overexpression, according to previous
reports (21).  2 test was used to analyze the data with respect
to clinicopathological parameters, such as T stage, lymph
node metastasis, and tumor site. P values less than 0.05 was
considered significant.
RESULTS
MUC1 was expressed intraluminally with the glycocalyx
and in intracytoplasmic lumina in colorectal carcinomas
(Fig. 1). Of 97 cancers, 45% (44/97) had a MUC1 score of 3
or more. MUC1 positivity was observed in 17% (2/12) of
pT1, 24% (5/21) of pT2, 57% (35/61) of pT3, and 67%
(2/3) of pT4 cancers. There was a significantly high frequency
of MUC1 positivity with respect to depth of tumor invasion
(Table 1, p=0.04). In 44 cases with lymph node metastasis,
MUC1 positivity was 57% (25/44). MUC1 positivity was
high in the group with lymph node metastasis (57% vs 32%,
p=0.04) (Table 1).
MUC2 expression was demonstrated along the tumor cell
membrane border (Fig. 2). In 97 cancers, 39 (40%) had a
MUC2 score of 3 or more. MUC2 was not evident in extra-
cellular mucin. No difference was observed in the frequency
of MUC2 positivity with respect to depth of tumor invasion
and lymph node metastasis (Table 1).
The p53 overexpression was noted only in the nuclei (Fig. 3).
*: MUC1 positivity was higher in high T stage (p=0.04). 
� : MUC1 posi-
tivity was higher in lymph node metastasis group (N1, 2) (p=0.04). 
� :
The right colon cancers showed a higher MUC1 positivity than the left
colon cancers (p=0.001).
MUC 1 MUC 2 p53
Depth of invasion
T1 2/12 (17%) 5/12 (42%) 3/12 (25%)
T2 5/21 (24%) 7/21 (33%) 13/21 (61%)
T3 35/61 (57%) 26/61 (43%) 40/61 (66%)
T4 2/3 (67%) 1/3 (33%) 2/3 (67%)
Regional lymph node
N0 17/53 (32%) 20/53 (38%) 32/53 (60%)
N1, 2 25/44 (57%)
� 19/44 (43%) 25/44 (57%)
Tumor site
Left 24/72 (33%) 27/72 (38%) 43/72 (60%)
Right 18/25 (72%)
� 12/25 (48%) 15/25 (60%)
Table 1. MUC 1, MUC 2, and p53 immunostaining and clinico-
pathological factors
*
Fig. 1. In immunostaining, MUC1 was expressed in the intralumi-
nal border of colorectal carcinoma (×200).Coexpression of MUC1 with p53 or MUC2 in Colorectal Carcinomas 31
Of 97 cancers, 58 (60%) showed a p53 overexpression. Neither
the depth of tumor invasion nor the lymph node metastasis
had a positive correlation with p53 overexpression (Table 1).
In 58 cases with p53 overexpression, 26 cases showed MUC1
positivity. In these 26 cases with coexpression of p53 and
MUC1, lymph node meatastasis was higher than those 35
cases with p53 overexpression and negative MUC1 (61% vs
31%, p=0.04) (Table 2). MUC2 expression had no positive
correlation with p53 overexpression with respect to tumor
invasion and lymph node metastasis. But combined with
MUC1 expression, subgroup of MUC1+/MUC2+ showed
a significant high frequency of lymph node metastasis than
subgroup of MUC1+/MUC2- (75% vs 37%, p=0.002)
(Table 3).
The frequency of MUC1-positive cells in right colon can-
cers was significantly higher than that in left colon cancers
(72% vs 33%; p=0.001) (Table 1). In contrast, the frequen-
cy of MUC2- or p53-positive cells showed no difference
according to the tumor site.
DISCUSSION
The present study showed that the MUC1 expression had
a significant correlation with the depth of tumor invasion
and lymph node metastasis in colorectal carcinomas. This
result is consistent with previous reports about up-regula-
tion of MUC1 expression in colorectal carcinomas (19, 20).
MUC2 apomucin is commonly expressed in mucinous car-
cinomas of the colon, pancreas, breast and ovary (22). But,
MUC2 apomucin is down-regulated in non-mucinous ade-
nocarcinoma of the colorectum (13, 14). In this study, down-
regulation of MUC2 apomucin has no correlation with
tumor invasion, lymph node metastasis and tumor site, but
combined with MUC1 expression, dual expression of MUC1
and MUC2 was related with regional lymph node metasta-
sis. Colon cancers with mucin phenotype of MUC1+/MUC2-
has been reported to be associated with peritumoral lym-
phocytic infiltration, thus it is suggested that MUC2 apo-
mucin have immunosuppressant effect (20). MUC2 apo-
mucins bear the sialosyl-Tn antigen, which is known to
mediate the inhibition of natural killer cell cytotoxicity (23).
Fig. 2. In immunostaining, MUC2 was expressed in perinuclear
cell membrane border (×200).
Fig. 3. In immunostainig, overexpression of p53 was noted in
nuclei of colorectal carcinoma cells (×100).
*: In cases with p53 overexpression, coexpression of MUC1 was relat-
ed to lymph node metastasis (p=0.04).
p53 (+)
MUC1 (-) MUC1 (+)
N0 22 (69%) 10 (39%)
N1, 2 10 (31%) 16 (61%)*
Table 2. Relationship of p53 and MUC1 with lymph node
metastasis
*: Colon cancers with dual expression of MUC1 and MUC2 were relat-
ed to lymph node metastasis (p=0.002).
MUC1+/MUC2- MUC1+/MUC2+
N0 15 (62%) 4 (25%)
N1, 2 9 (38%) 12 (75%)*
Table 3. Relation between MUC phenotypes and lymph node
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It is suggested that these immunosuppressant effect of MUC2
apomucin seems to be related with high frequency of regional
lymph node metastasis in colorectal non-mucinous adeno-
carcinomas of MUC1 expression cases.
Overexpression of p53 is frequently noted in a variety of
malignant neoplasms and metastatic tumors including col-
orectal carcinomas. Whether the p53 overexpression is a
prognostic indicator or not remains controversial (16, 17).
In this study, the frequency of p53 overexpression showed
no difference in tumor invasion and lymph node metastasis.
However the cancers with coexpression of MUC1 with p53
or MUC2 could be considered a high-risk group for lymph
node metastasis.
An interesting result of the present study was the signifi-
cantly high frequency of MUC1 positivity in the right side
colon cancers. There have been few reports about high fre-
quency of MUC1 expression in right colon cancers. It has
been reported that most mucin-carbohydrate component
consists of sulfomucin in the left side colon, and sialomucin
in the right side colon (24, 25). Tumor cells expressing sialo-
mucin have been shown to be less sensitive to cytolysis by
human lymphokine-activated killer lymphocytes (23, 26).
Thus the high level of cell surface sialomucin of the right
side colon cancers may contribute to the escape from the
immunological attack, resulting in an increased metastatic
colonization of cancer cells (27, 28). In this study, right colon
cancers showed a significantly high frequency of lymph node
metastasis than left colon cancers. Thus up-regulation of
sialylated MUC1 mucin in right colon cancers is suggested
to relate with high frequency of regional lymph node meta-
stasis. In cholangiocarcinomas of the liver, it has been
reported that the expression of sialylated MUC1 mucin is
strongly correlated with a poor outcome of patient (29).
The aim of this study was to determine the value of MUC1,
MUC2, and p53 immunostaining as a marker to predict
metastatic potential in colorectal cancers. In conclusion, this
study revealed that MUC1 positivity and coexpression with
p53 or MUC2 could be useful markers for metastatic poten-
tial in colorectal carcinomas.
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